25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ELDN (Eledon) Stock Analysis
Buy, Hold or Sell?

Let's analyze Eledon together

I guess you are interested in Eledon Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Eledon’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Eledon’s Price Targets

I'm going to help you getting a better view of Eledon Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Eledon Pharmaceuticals Inc

I send you an email if I find something interesting about Eledon Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Eledon (30 sec.)










1.2. What can you expect buying and holding a share of Eledon? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.15
Expected worth in 1 year
$-0.95
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$-1.10
Return On Investment
-35.7%

For what price can you sell your share?

Current Price per Share
$3.08
Expected price per share
$2.42 - $3.51
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Eledon (5 min.)




Live pricePrice per Share (EOD)
$3.08
Intrinsic Value Per Share
$-2.23 - $2.61
Total Value Per Share
$-2.08 - $2.76

2.2. Growth of Eledon (5 min.)




Is Eledon growing?

Current yearPrevious yearGrowGrow %
How rich?$114.5m$87.3m-$12.3m-16.4%

How much money is Eledon making?

Current yearPrevious yearGrowGrow %
Making money-$4.7m-$9.9m$5.2m109.2%
Net Profit Margin-7,814.3%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Eledon (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#331 / 884

Most Revenue
#543 / 884

Most Profit
#410 / 884

Most Efficient
#822 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Eledon?

Welcome investor! Eledon's management wants to use your money to grow the business. In return you get a share of Eledon.

First you should know what it really means to hold a share of Eledon. And how you can make/lose money.

Speculation

The Price per Share of Eledon is $3.08. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Eledon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Eledon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.15. Based on the TTM, the Book Value Change Per Share is $-0.28 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Eledon.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.01-0.3%-0.05-1.8%-0.17-5.4%-0.13-4.2%-0.13-4.1%-0.12-3.7%
Usd Book Value Change Per Share-1.82-59.2%-0.28-8.9%0.000.0%-0.21-6.7%0.00-0.1%-0.03-1.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.82-59.2%-0.28-8.9%0.000.0%-0.21-6.7%0.00-0.1%-0.03-1.1%
Usd Price Per Share3.39-3.16-1.65-2.42-3.95-4.15-
Price to Earnings Ratio-100.64--25.60--2.48--10.59--11.44--11.86-
Price-to-Total Gains Ratio-1.86-0.97--8.56--7.40--19.57-84.92-
Price to Book Ratio22.82-2.07-1.16-1.55-2.02-5.56-
Price-to-Total Gains Ratio-1.86-0.97--8.56--7.40--19.57-84.92-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.08
Number of shares324
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.280.00
Usd Total Gains Per Share-0.280.00
Gains per Quarter (324 shares)-89.17-0.77
Gains per Year (324 shares)-356.69-3.08
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-357-3670-3-13
20-713-7240-6-16
30-1070-10810-9-19
40-1427-14380-12-22
50-1783-17950-15-25
60-2140-21520-18-28
70-2497-25090-22-31
80-2853-28660-25-34
90-3210-32230-28-37
100-3567-35800-31-40

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%1.045.00.02.2%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%5.015.00.025.0%9.031.00.022.5%12.033.01.026.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.046.00.0%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%5.015.00.025.0%9.031.00.022.5%12.033.01.026.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Eledon Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.824-0.275-85%0.000-1618528%-0.205-89%-0.002-100%-0.034-98%
Book Value Per Share--0.1490.812-82%1.459-90%1.383-89%1.727-91%1.110-87%
Current Ratio--13.90511.831+18%15.615-11%13.407+4%18.508-25%14.097-1%
Debt To Asset Ratio--0.2900.508-43%0.131+121%0.236+23%0.202+43%0.159+83%
Debt To Equity Ratio--0.4080.354+15%0.177+130%0.202+102%0.536-24%0.335+22%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--2692750265.700830467228.925+224%140031720.000+1823%390044308.975+590%408187542.705+560%346750929.133+677%
Eps---0.008-0.055+547%-0.166+1876%-0.129+1436%-0.127+1407%-0.115+1266%
Ev To Ebitda Ratio---37.474-11.267-70%-3.303-91%-6.504-83%-9.499-75%-13.998-63%
Free Cash Flow Per Share---0.021-0.166+698%-0.160+669%-0.151+624%-0.132+535%-0.112+438%
Free Cash Flow To Equity Per Share---0.0210.391-105%-0.022+8%0.219-109%0.255-108%0.096-122%
Gross Profit Margin--1.0001.0010%1.0050%1.0020%1.0010%1.077-7%
Intrinsic Value_10Y_max--2.607----------
Intrinsic Value_10Y_min---2.226----------
Intrinsic Value_1Y_max---0.346----------
Intrinsic Value_1Y_min---0.542----------
Intrinsic Value_3Y_max---0.577----------
Intrinsic Value_3Y_min---1.362----------
Intrinsic Value_5Y_max---0.250----------
Intrinsic Value_5Y_min---1.883----------
Market Cap184435944.000-1318%2614597265.700792125978.925+230%98804970.000+2546%346080058.975+655%357196842.705+632%308667679.133+747%
Net Profit Margin----78.1430%-0%-26.0480%-3693.3560%-1846.6780%
Operating Margin----38.6300%-0%-12.8770%-3926.7840%-1963.3920%
Operating Ratio---38.424-100%-0%12.808-100%3951.749-100%1975.875-100%
Pb Ratio20.732-10%22.8192.068+1004%1.165+1859%1.549+1373%2.022+1029%5.558+311%
Pe Ratio-91.436+9%-100.639-25.604-75%-2.479-98%-10.590-89%-11.444-89%-11.858-88%
Price Per Share3.080-10%3.3903.160+7%1.650+105%2.423+40%3.951-14%4.148-18%
Price To Free Cash Flow Ratio-36.979+9%-40.700-13.050-68%-2.662-93%-7.077-83%-10.567-74%-11.716-71%
Price To Total Gains Ratio-1.688+9%-1.8580.968-292%-8.556+360%-7.400+298%-19.570+953%84.919-102%
Quick Ratio--26.26721.031+25%26.136+1%19.822+33%22.143+19%16.146+63%
Return On Assets---0.0400.002-2306%-0.100+149%-0.106+164%-0.092+128%-0.155+284%
Return On Equity---0.0570.144-139%-0.116+104%-0.071+25%-0.085+50%-0.168+197%
Total Gains Per Share---1.824-0.275-85%0.000-1618528%-0.205-89%-0.002-100%-0.034-98%
Usd Book Value--114580000.00075069250.000+53%87380500.000+31%91603833.333+25%108707850.000+5%69099375.000+66%
Usd Book Value Change Per Share---1.824-0.275-85%0.000-1618528%-0.205-89%-0.002-100%-0.034-98%
Usd Book Value Per Share--0.1490.812-82%1.459-90%1.383-89%1.727-91%1.110-87%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--2692750265.700830467228.925+224%140031720.000+1823%390044308.975+590%408187542.705+560%346750929.133+677%
Usd Eps---0.008-0.055+547%-0.166+1876%-0.129+1436%-0.127+1407%-0.115+1266%
Usd Free Cash Flow---16060000.000-13647500.000-15%-9586000.000-40%-10260500.000-36%-8660500.000-46%-7082225.050-56%
Usd Free Cash Flow Per Share---0.021-0.166+698%-0.160+669%-0.151+624%-0.132+535%-0.112+438%
Usd Free Cash Flow To Equity Per Share---0.0210.391-105%-0.022+8%0.219-109%0.255-108%0.096-122%
Usd Market Cap184435944.000-1318%2614597265.700792125978.925+230%98804970.000+2546%346080058.975+655%357196842.705+632%308667679.133+747%
Usd Price Per Share3.080-10%3.3903.160+7%1.650+105%2.423+40%3.951-14%4.148-18%
Usd Profit---6495000.000-4762000.000-27%-9962250.000+53%-12244583.333+89%-10297200.000+59%-8239775.000+27%
Usd Revenue---188000.000-100%-0%62666.667-100%55606.000-100%27803.000-100%
Usd Total Gains Per Share---1.824-0.275-85%0.000-1618528%-0.205-89%-0.002-100%-0.034-98%
 EOD+3 -5MRQTTM+16 -19YOY+19 -143Y+19 -165Y+19 -1610Y+17 -18

3.3 Fundamental Score

Let's check the fundamental score of Eledon Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-91.436
Price to Book Ratio (EOD)Between0-120.732
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than126.267
Current Ratio (MRQ)Greater than113.905
Debt to Asset Ratio (MRQ)Less than10.290
Debt to Equity Ratio (MRQ)Less than10.408
Return on Equity (MRQ)Greater than0.15-0.057
Return on Assets (MRQ)Greater than0.05-0.040
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Eledon Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.254
Ma 20Greater thanMa 502.860
Ma 50Greater thanMa 1002.996
Ma 100Greater thanMa 2003.318
OpenGreater thanClose3.080
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Fundamental data was last updated by Penke on 2025-06-19 04:48:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Eledon earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Eledon to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-7,814.3%+7,814.3%
TTM-7,814.3%YOY--7,814.3%
TTM-7,814.3%5Y-369,335.6%+361,521.4%
5Y-369,335.6%10Y-184,667.8%-184,667.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--91.7%+91.7%
TTM-7,814.3%-139.0%-7,675.3%
YOY--194.4%+194.4%
3Y-2,604.8%-248.5%-2,356.3%
5Y-369,335.6%-343.3%-368,992.3%
10Y-184,667.8%-488.9%-184,178.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Eledon is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Eledon to theΒ Biotechnology industry mean.
  • -4.0% Return on Assets means thatΒ Eledon generatedΒ $-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Eledon Pharmaceuticals Inc:

  • The MRQ is -4.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.2%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-4.0%TTM0.2%-4.2%
TTM0.2%YOY-10.0%+10.2%
TTM0.2%5Y-9.2%+9.4%
5Y-9.2%10Y-15.5%+6.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.0%-11.6%+7.6%
TTM0.2%-11.7%+11.9%
YOY-10.0%-11.4%+1.4%
3Y-10.6%-11.9%+1.3%
5Y-9.2%-12.1%+2.9%
10Y-15.5%-13.8%-1.7%
4.3.1.3. Return on Equity

Shows how efficient Eledon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Eledon to theΒ Biotechnology industry mean.
  • -5.7% Return on Equity means Eledon generated $-0.06Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Eledon Pharmaceuticals Inc:

  • The MRQ is -5.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 14.4%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ-5.7%TTM14.4%-20.1%
TTM14.4%YOY-11.6%+26.0%
TTM14.4%5Y-8.5%+23.0%
5Y-8.5%10Y-16.8%+8.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.7%-13.5%+7.8%
TTM14.4%-15.0%+29.4%
YOY-11.6%-14.5%+2.9%
3Y-7.1%-16.9%+9.8%
5Y-8.5%-17.9%+9.4%
10Y-16.8%-19.9%+3.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Eledon Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Eledon is operatingΒ .

  • Measures how much profit Eledon makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Eledon to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-3,863.0%+3,863.0%
TTM-3,863.0%YOY--3,863.0%
TTM-3,863.0%5Y-392,678.4%+388,815.3%
5Y-392,678.4%10Y-196,339.2%-196,339.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM-3,863.0%-249.7%-3,613.3%
YOY--208.4%+208.4%
3Y-1,287.7%-221.7%-1,066.0%
5Y-392,678.4%-344.1%-392,334.3%
10Y-196,339.2%-470.4%-195,868.8%
4.3.2.2. Operating Ratio

Measures how efficient Eledon is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM38.424-38.424
TTM38.424YOY-+38.424
TTM38.4245Y3,951.749-3,913.326
5Y3,951.74910Y1,975.875+1,975.875
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.108-2.108
TTM38.4242.680+35.744
YOY-3.080-3.080
3Y12.8083.621+9.187
5Y3,951.7494.734+3,947.015
10Y1,975.8756.546+1,969.329
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Eledon Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Eledon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 13.91Β means the company has $13.91 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 13.905. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.831. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.905TTM11.831+2.074
TTM11.831YOY15.615-3.784
TTM11.8315Y18.508-6.677
5Y18.50810Y14.097+4.411
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.9053.659+10.246
TTM11.8313.834+7.997
YOY15.6154.141+11.474
3Y13.4074.661+8.746
5Y18.5085.756+12.752
10Y14.0976.151+7.946
4.4.3.2. Quick Ratio

Measures if Eledon is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Eledon to theΒ Biotechnology industry mean.
  • A Quick Ratio of 26.27Β means the company can pay off $26.27 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 26.267. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 21.031. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ26.267TTM21.031+5.237
TTM21.031YOY26.136-5.106
TTM21.0315Y22.143-1.112
5Y22.14310Y16.146+5.997
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ26.2672.799+23.468
TTM21.0313.143+17.888
YOY26.1363.794+22.342
3Y19.8224.307+15.515
5Y22.1435.707+16.436
10Y16.1466.457+9.689
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Eledon Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of EledonΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Eledon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.29Β means that Eledon assets areΒ financed with 29.0% credit (debt) and the remaining percentage (100% - 29.0%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.290. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.508. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.290TTM0.508-0.218
TTM0.508YOY0.131+0.376
TTM0.5085Y0.202+0.306
5Y0.20210Y0.159+0.043
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2900.324-0.034
TTM0.5080.347+0.161
YOY0.1310.329-0.198
3Y0.2360.340-0.104
5Y0.2020.349-0.147
10Y0.1590.379-0.220
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Eledon is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Eledon to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 40.8% means that company has $0.41 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.408. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.354. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.408TTM0.354+0.054
TTM0.354YOY0.177+0.177
TTM0.3545Y0.536-0.182
5Y0.53610Y0.335+0.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4080.379+0.029
TTM0.3540.435-0.081
YOY0.1770.412-0.235
3Y0.2020.446-0.244
5Y0.5360.460+0.076
10Y0.3350.509-0.174
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Eledon generates.

  • Above 15 is considered overpriced butΒ always compareΒ Eledon to theΒ Biotechnology industry mean.
  • A PE ratio of -100.64 means the investor is paying $-100.64Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Eledon Pharmaceuticals Inc:

  • The EOD is -91.436. Based on the earnings, the company is expensive. -2
  • The MRQ is -100.639. Based on the earnings, the company is expensive. -2
  • The TTM is -25.604. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-91.436MRQ-100.639+9.203
MRQ-100.639TTM-25.604-75.035
TTM-25.604YOY-2.479-23.125
TTM-25.6045Y-11.444-14.161
5Y-11.44410Y-11.858+0.415
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-91.436-2.282-89.154
MRQ-100.639-2.062-98.577
TTM-25.604-2.541-23.063
YOY-2.479-3.722+1.243
3Y-10.590-3.754-6.836
5Y-11.444-6.100-5.344
10Y-11.858-6.653-5.205
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Eledon Pharmaceuticals Inc:

  • The EOD is -36.979. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -40.700. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -13.050. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-36.979MRQ-40.700+3.722
MRQ-40.700TTM-13.050-27.650
TTM-13.050YOY-2.662-10.388
TTM-13.0505Y-10.567-2.483
5Y-10.56710Y-11.716+1.149
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-36.979-3.101-33.878
MRQ-40.700-2.689-38.011
TTM-13.050-3.594-9.456
YOY-2.662-4.363+1.701
3Y-7.077-5.065-2.012
5Y-10.567-8.478-2.089
10Y-11.716-9.273-2.443
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Eledon is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 22.82 means the investor is paying $22.82Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Eledon Pharmaceuticals Inc:

  • The EOD is 20.732. Based on the equity, the company is expensive. -2
  • The MRQ is 22.819. Based on the equity, the company is expensive. -2
  • The TTM is 2.068. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD20.732MRQ22.819-2.087
MRQ22.819TTM2.068+20.751
TTM2.068YOY1.165+0.903
TTM2.0685Y2.022+0.046
5Y2.02210Y5.558-3.536
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.7321.932+18.800
MRQ22.8191.848+20.971
TTM2.0682.119-0.051
YOY1.1652.469-1.304
3Y1.5492.526-0.977
5Y2.0223.667-1.645
10Y5.5584.351+1.207
4.6.2. Total Gains per Share

2.4. Latest News of Eledon Pharmaceuticals Inc

Does Eledon Pharmaceuticals Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Eledon Pharmaceuticals Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-25
22:01
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York CityRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Eledon Pharmaceuticals Inc.

4.8.1. Institutions holding Eledon Pharmaceuticals Inc

Institutions are holding 68.205% of the shares of Eledon Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Bvf Inc10.50950.8695629328200
2025-03-31RA Capital Management, LLC5.95560.2019356633800
2025-03-31Vanguard Group Inc4.93160.00022953127584882.0206
2025-03-31First Light Asset Management, LLC3.88890.9015232876800
2025-03-31Sphera Funds Management Ltd.3.85281.80082307119-244500-9.5822
2025-03-31Blue Owl Capital Holdings LP3.03921.98971819912-140000-7.1432
2025-03-31Woodline Partners LP2.79190.0369167182200
2024-12-31Schonfeld Strategic Advisors LLC2.53120.03631515750157501.05
2025-03-31Ensign Peak Advisors Inc2.11240.0082126491900
2025-03-31Nantahala Capital Management, LLC1.90580.15371141237-6709-0.5844
2025-03-31Awm Investment Company Inc1.83770.5138110047300
2025-03-31Ikarian Capital, LLC1.71210.42831025221-101416-9.0017
2025-03-31Alyeska Investment Group, L.P.1.55890.012693347500
2025-03-31Sanofi1.3611.664981498000
2025-03-31Millennium Management LLC1.35410.0015810876692015582.2053
2024-12-31Zimmer Partners LP1.25250.0532750000-684727-47.7252
2025-03-31Siren, L.L.C.1.15260.1326901706901700
2025-03-31Geode Capital Management, LLC1.11340.000266671736160.5453
2025-03-31BlackRock Inc1.08980.0001652621349975.6664
2025-03-3122NW, LP1.06271.4476363646363640
Total 55.013710.252332943171+954048+2.9%

4.9.2. Funds holding Eledon Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv3.14640.0004188414300
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.62820.00397499100
2025-04-30Fidelity Extended Market Index0.5470.0029327557-3131-0.9468
2025-03-31MEDICAL BioHealth EUR Acc0.49180.15282944852944850
2025-03-31Extended Equity Market Fund K0.20290.00311214983720.3071
2025-04-30IMC US Ultra Micro Cap0.2020.438412096400
2025-05-31iShares Micro-Cap ETF0.19680.045611786700
2025-04-30Fidelity Total Market Index0.18970.000411358600
2025-04-30Fidelity Series Total Market Index0.14040.00048406029373.6204
2025-03-31NT Ext Equity Mkt Idx Fd - L0.11940.00317150837885.5936
2025-03-31Northern Trust Extended Eq Market Idx0.11940.00317150837885.5936
2025-04-30Spartan Extended Market Index Pool F0.11210.00296715431314.8904
2025-03-31Pleiades Small Cap Equity A0.1010.02216048200
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.09730.00335825500
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.07570.003345348-826-1.7889
2025-02-28Vifag 2002 SICAV0.07290.26324364200
2025-05-30ALPS Medical Breakthroughs ETF0.07230.159943269-389-0.891
2025-04-30Spartan Total Market Index Pool G0.06520.000339019620.1591
2025-04-30Vanguard Balanced Index Inv0.06190.00023704000
2025-04-30Fidelity Nasdaq Composite Index0.05820.00073482800
Total 7.70061.10914611204+304217+6.6%

5.3. Insider Transactions

Insiders are holding 1.396% of the shares of Eledon Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-12-20David-alexandre C GrosBUY20004.48
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets161,308
Total Liabilities46,728
Total Stockholder Equity114,580
 As reported
Total Liabilities 46,728
Total Stockholder Equity+ 114,580
Total Assets = 161,308

Assets

Total Assets161,308
Total Current Assets127,718
Long-term Assets33,590
Total Current Assets
Cash And Cash Equivalents 8,496
Short-term Investments 116,385
Other Current Assets 2,837
Total Current Assets  (as reported)127,718
Total Current Assets  (calculated)127,718
+/-0
Long-term Assets
Property Plant Equipment 850
Intangible Assets 32,386
Long-term Assets  (as reported)33,590
Long-term Assets  (calculated)33,236
+/- 354

Liabilities & Shareholders' Equity

Total Current Liabilities9,185
Long-term Liabilities37,543
Total Stockholder Equity114,580
Total Current Liabilities
Short-term Debt 325
Accounts payable 2,901
Other Current Liabilities 3,058
Total Current Liabilities  (as reported)9,185
Total Current Liabilities  (calculated)6,284
+/- 2,901
Long-term Liabilities
Capital Lease Obligations 880
Long-term Liabilities  (as reported)37,543
Long-term Liabilities  (calculated)880
+/- 36,663
Total Stockholder Equity
Common Stock60
Retained Earnings -362,081
Accumulated Other Comprehensive Income -18
Other Stockholders Equity 476,619
Total Stockholder Equity (as reported)114,580
Total Stockholder Equity (calculated)114,580
+/-0
Other
Capital Stock60
Cash and Short Term Investments 124,881
Common Stock Shares Outstanding 771,268
Liabilities and Stockholders Equity 161,308
Net Debt -7,616
Net Invested Capital 114,580
Net Working Capital 118,533
Property Plant and Equipment Gross 850
Short Long Term Debt Total 880



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-30
> Total Assets 
0
32,287
0
23,420
106,983
107,744
96,650
87,410
77,607
67,974
57,710
46,857
36,721
29,761
25,831
26,844
23,019
20,892
25,917
22,965
19,928
17,026
13,451
18,216
15,218
10,931
13,720
10,501
192,585
197,185
191,682
184,305
177,170
170,548
161,378
154,706
149,586
92,793
82,306
106,785
96,069
125,894
80,818
120,483
114,576
177,405
161,308
161,308177,405114,576120,48380,818125,89496,069106,78582,30692,793149,586154,706161,378170,548177,170184,305191,682197,185192,58510,50113,72010,93115,21818,21613,45117,02619,92822,96525,91720,89223,01926,84425,83129,76136,72146,85757,71067,97477,60787,41096,650107,744106,98323,420032,2870
   > Total Current Assets 
0
32,178
0
21,739
106,724
107,511
96,332
86,756
76,865
67,170
56,987
46,186
36,334
29,543
25,631
24,843
21,035
19,000
24,028
21,078
17,110
14,276
10,321
15,181
12,296
9,971
12,873
9,761
115,101
115,630
110,241
102,582
95,558
88,346
79,325
72,788
67,565
59,518
48,904
73,622
62,991
56,129
47,977
87,221
81,509
143,730
127,718
127,718143,73081,50987,22147,97756,12962,99173,62248,90459,51867,56572,78879,32588,34695,558102,582110,241115,630115,1019,76112,8739,97112,29615,18110,32114,27617,11021,07824,02819,00021,03524,84325,63129,54336,33446,18656,98767,17076,86586,75696,332107,511106,72421,739032,1780
       Cash And Cash Equivalents 
0
31,753
0
21,150
105,464
105,256
94,162
59,084
33,168
24,023
14,303
12,156
18,630
23,223
24,400
22,498
19,094
17,233
22,523
19,189
16,324
12,972
9,056
13,703
10,814
8,791
11,785
8,764
114,464
114,195
108,579
101,133
94,041
84,833
76,677
70,460
65,889
56,409
46,485
40,947
3,667
4,612
5,655
26,039
6,751
20,549
8,496
8,49620,5496,75126,0395,6554,6123,66740,94746,48556,40965,88970,46076,67784,83394,041101,133108,579114,195114,4648,76411,7858,79110,81413,7039,05612,97216,32419,18922,52317,23319,09422,49824,40023,22318,63012,15614,30324,02333,16859,08494,162105,256105,46421,150031,7530
       Short-term Investments 
0
0
0
0
0
0
0
24,110
39,935
39,934
39,947
31,771
16,088
4,175
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,431
55,942
46,490
37,207
57,571
71,440
119,629
116,385
116,385119,62971,44057,57137,20746,49055,94230,43100000000000000000000000024,17516,08831,77139,94739,93439,93524,1100000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
594
747
739
956
245
247
162
214
110
197
87
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000087197110214162247245956739747594000000000000000000000
       Other Current Assets 
0
425
0
589
1,260
2,255
2,170
3,562
3,762
3,213
2,737
4,518
1,616
2,145
1,231
2,345
3,882
0
1,505
1,889
786
1,304
518
739
526
935
841
835
423
1,325
1,465
1,362
1,517
3,513
2,648
2,328
1,676
3,109
2,419
2,244
3,382
5,027
5,115
3,611
3,318
3,552
2,837
2,8373,5523,3183,6115,1155,0273,3822,2442,4193,1091,6762,3282,6483,5131,5171,3621,4651,3254238358419355267395181,3047861,8891,50503,8822,3451,2312,1451,6164,5182,7373,2133,7623,5622,1702,2551,26058904250
   > Long-term Assets 
0
109
0
1,681
259
233
318
654
742
804
723
671
387
218
200
2,001
1,984
1,892
1,889
1,887
2,818
2,750
3,130
3,035
2,922
960
847
740
77,484
81,555
81,441
81,723
81,612
82,202
82,053
81,918
82,021
33,275
33,402
33,163
33,078
69,765
32,841
33,262
33,067
33,675
33,590
33,59033,67533,06733,26232,84169,76533,07833,16333,40233,27582,02181,91882,05382,20281,61281,72381,44181,55577,4847408479602,9223,0353,1302,7502,8181,8871,8891,8921,9842,0012002183876717238047426543182332591,68101090
       Property Plant Equipment 
0
29
0
36
38
33
73
339
427
489
453
401
117
98
80
49
47
25
22
20
17
14
458
413
367
321
275
229
183
138
92
267
222
768
675
581
832
739
647
553
459
365
270
621
471
926
850
85092647162127036545955364773983258167576822226792138183229275321367413458141720222547498098117401453489427339733338360290
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,867
1,867
1,867
1,867
1,867
1,867
1,867
1,867
1,867
1,867
0
0
0
44,466
48,648
48,648
48,648
48,648
48,648
48,648
48,648
48,648
0
0
0
0
0
0
0
0
0
0
000000000048,64848,64848,64848,64848,64848,64848,64848,64844,4660001,8671,8671,8671,8671,8671,8671,8671,8671,8671,867000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,3860000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
639
0
511
33,018
32,907
315
422
356
400
344
303
155
0
0
224
0
0
0
0
0
0
0
00000002240015530334440035642231532,90733,01851106390000000000000000000000000
> Total Liabilities 
0
87,554
0
3,688
5,372
4,243
5,754
4,660
5,708
6,250
6,303
7,973
6,464
2,903
2,467
3,405
2,400
1,440
1,619
1,452
1,603
2,534
3,522
2,184
1,852
1,466
1,975
1,145
171,079
6,589
7,811
5,784
6,422
6,553
5,060
5,327
8,493
8,610
7,514
6,836
4,734
42,475
5,999
128,984
38,518
59,265
46,728
46,72859,26538,518128,9845,99942,4754,7346,8367,5148,6108,4935,3275,0606,5536,4225,7847,8116,589171,0791,1451,9751,4661,8522,1843,5222,5341,6031,4521,6191,4402,4003,4052,4672,9036,4647,9736,3036,2505,7084,6605,7544,2435,3723,688087,5540
   > Total Current Liabilities 
0
2,209
0
3,688
5,372
4,243
5,754
4,647
5,657
6,162
6,177
7,817
6,344
2,819
2,419
3,160
2,306
1,440
1,619
1,452
1,603
2,534
3,241
1,948
1,661
1,322
1,878
1,097
6,130
2,483
4,206
2,677
4,046
4,401
2,958
3,276
6,280
6,475
5,478
4,900
2,899
3,895
4,247
6,025
12,489
11,577
9,185
9,18511,57712,4896,0254,2473,8952,8994,9005,4786,4756,2803,2762,9584,4014,0462,6774,2062,4836,1301,0971,8781,3221,6611,9483,2412,5341,6031,4521,6191,4402,3063,1602,4192,8196,3447,8176,1776,1625,6574,6475,7544,2435,3723,68802,2090
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
3
3,447
0
0
0
0
0
0
0
0
340
346
354
180
368
376
382
288
194
358
354
738
656
574
756
726
768
780
792
383
284
538
186
628
325
325628186538284383792780768726756574656738354358194288382376368180354346340000000003,4473000000000000
       Accounts payable 
0
5
0
1,216
2,889
765
3,434
1,704
1,652
1,208
1,886
1,846
886
338
276
374
189
0
449
706
751
689
480
753
256
329
741
150
758
1,366
1,514
857
1,598
1,813
1,026
1,318
3,859
2,200
2,852
2,197
465
967
1,864
2,148
5,860
5,833
2,901
2,9015,8335,8602,1481,8649674652,1972,8522,2003,8591,3181,0261,8131,5988571,5141,36675815074132925675348068975170644901893742763388861,8461,8861,2081,6521,7043,4347652,8891,216050
       Other Current Liabilities 
0
2,204
0
2,472
2,483
3,478
2,320
2,943
4,005
4,954
4,291
5,971
5,458
-966
2,143
2,786
2,117
0
1,170
746
852
1,845
2,421
849
1,051
813
769
571
4,990
829
2,498
1,462
2,094
1,850
1,276
1,384
1,665
3,549
1,858
1,923
1,642
2,545
2,099
3,339
6,443
5,430
3,058
3,0585,4306,4433,3392,0992,5451,6421,9231,8583,5491,6651,3841,2761,8502,0941,4622,4988294,9905717698131,0518492,4211,8458527461,17002,1172,7862,143-9665,4585,9714,2914,9544,0052,9432,3203,4782,4832,47202,2040
   > Long-term Liabilities 
0
85,345
0
0
0
0
0
13
51
88
126
156
120
84
48
245
94
0
1,170
746
852
1,845
281
236
191
144
97
48
164,949
4,106
3,605
3,107
2,376
2,152
2,102
2,051
2,213
2,135
2,036
1,936
1,835
38,580
1,752
122,959
26,029
47,688
37,543
37,54347,68826,029122,9591,75238,5801,8351,9362,0362,1352,2132,0512,1022,1522,3763,1073,6054,106164,94948971441912362811,8458527461,17009424548841201561268851130000085,3450
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,106
3,605
3,017
2,331
1,752
1,752
1,752
1,752
0
0
1,752
0
0
0
0
0
0
0
00000001,752001,7521,7521,7521,7522,3313,0173,6054,10600000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,752
0
0
0
0
0
0
0
0
000000001,75200000000000000000000000000000000000000
> Total Stockholder Equity
0
-55,267
0
19,732
101,611
103,501
90,896
82,750
71,899
61,724
51,407
38,884
30,257
26,858
23,364
23,439
20,619
0
24,298
21,513
18,325
14,492
9,929
16,032
13,366
9,465
11,745
9,356
21,506
190,596
183,871
178,521
170,748
163,995
156,318
149,379
141,093
84,183
74,792
99,949
91,335
83,419
74,819
-8,501
76,058
118,140
114,580
114,580118,14076,058-8,50174,81983,41991,33599,94974,79284,183141,093149,379156,318163,995170,748178,521183,871190,59621,5069,35611,7459,46513,36616,0329,92914,49218,32521,51324,298020,61923,43923,36426,85830,25738,88451,40761,72471,89982,75090,896103,501101,61119,7320-55,2670
   Common Stock
0
0
0
15
22
22
22
22
23
23
23
23
23
23
23
7
7
0
9
9
9
9
9
13
13
13
16
19
1
15
14
14
14
14
14
14
14
14
14
23
24
24
25
39
41
60
60
6060413925242423141414141414141414151191613131399999077232323232323232222222215000
   Retained Earnings Total Equity00000000-213,63700000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
-43
0
0
-106,983
-58
0
-2
8
-55
-5
6
3
-1
-3
0
0
0
0
0
0
0
0
0
0
0
0
0
-90,460
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
102
26
-18
-1826102000000000000000-90,4600000000000000-3-136-5-558-20-58-106,98300-430
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
288,415
0
0
0
0
0
0
0
0
00000000288,41500000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
7,831
0
93,470
74,749
189,830
190,485
191,298
192,289
193,194
194,253
195,245
195,891
196,233
196,604
45,858
46,008
0
54,601
55,005
55,313
56,054
56,372
66,564
66,791
67,034
77,488
77,682
-68,955
270,974
272,749
274,783
276,827
278,880
281,067
283,375
285,560
287,034
288,415
323,142
324,876
326,586
328,280
379,400
386,884
473,640
476,619
476,619473,640386,884379,400328,280326,586324,876323,142288,415287,034285,560283,375281,067278,880276,827274,783272,749270,974-68,95577,68277,48867,03466,79166,56456,37256,05455,31355,00554,601046,00845,858196,604196,233195,891195,245194,253193,194192,289191,298190,485189,83074,74993,47007,8310



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-374
Gross Profit-374-374
 
Operating Income (+$)
Gross Profit-374
Operating Expense-70,577
Operating Income-70,577-70,951
 
Operating Expense (+$)
Research Development51,964
Selling General Administrative18,613
Selling And Marketing Expenses0
Operating Expense70,57770,577
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-70,577
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-35,753-105,401
EBIT - interestExpense = -35,753
-34,891
-35,322
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-35,753-35,753
Earnings Before Interest and Taxes (EBITDA)-35,394
 
After tax Income (+$)
Income Before Tax-35,753
Tax Provision-431
Net Income From Continuing Ops-36,184-36,184
Net Income-35,322
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses70,577
Total Other Income/Expenses Net34,8240
 

Technical Analysis of Eledon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Eledon. The general trend of Eledon is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Eledon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Eledon Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Eledon Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.265 < 3.27 < 3.51.

The bearish price targets are: 2.6 > 2.42 > 2.42.

Know someone who trades $ELDN? Share this with them.πŸ‘‡

Eledon Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Eledon Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Eledon Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Eledon Pharmaceuticals Inc. The current macd is -0.03407175.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Eledon price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Eledon. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Eledon price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Eledon Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartEledon Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Eledon Pharmaceuticals Inc. The current adx is 14.27.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Eledon shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Eledon Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Eledon Pharmaceuticals Inc. The current sar is 2.6093.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Eledon Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Eledon Pharmaceuticals Inc. The current rsi is 59.25. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Eledon Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartEledon Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Eledon Pharmaceuticals Inc. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Eledon price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Eledon Pharmaceuticals Inc Daily Stochastic Oscillator ChartEledon Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Eledon Pharmaceuticals Inc. The current cci is 119.02.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Eledon Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartEledon Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Eledon Pharmaceuticals Inc. The current cmo is 35.15.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Eledon Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartEledon Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Eledon Pharmaceuticals Inc. The current willr is -14.28571429.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Eledon Pharmaceuticals Inc Daily Williams %R ChartEledon Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Eledon Pharmaceuticals Inc. The current atr is 0.18326242.

Eledon Pharmaceuticals Inc Daily Average True Range (ATR) ChartEledon Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Eledon Pharmaceuticals Inc. The current obv is 14,273,225.

Eledon Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartEledon Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Eledon Pharmaceuticals Inc. The current mfi is 22.31.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Eledon Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartEledon Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Eledon Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-24BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-10BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Eledon Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Eledon Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.254
Ma 20Greater thanMa 502.860
Ma 50Greater thanMa 1002.996
Ma 100Greater thanMa 2003.318
OpenGreater thanClose3.080
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Eledon with someone you think should read this too:
  • Are you bullish or bearish on Eledon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Eledon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Eledon Pharmaceuticals Inc

I send you an email if I find something interesting about Eledon Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Eledon Pharmaceuticals Inc.

Receive notifications about Eledon Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.